Gilead locks in Daniel O'­Day as CEO, tap­ping the Roche vet to re­ju­ve­nate growth

The sus­pense over who will suc­ceed John Mil­li­gan at Gilead has fi­nal­ly end­ed.

Daniel O’Day, cur­rent CEO of Roche’s Phar­ma di­vi­sion, has been tapped for the top job, Gilead an­nounced days be­fore Mil­li­gan is set to de­part from his cor­ner of­fice.

John Mil­li­gan

O’Day’s ap­point­ment ush­ers in a new era for the Fos­ter City, CA-based big biotech, which Mil­li­gan and his pre­de­ces­sor, John Mar­tin, ran for near­ly three decades, cre­at­ing an HIV pow­er­house and an in­dus­try-dom­i­nat­ing he­pati­tis C fran­chise. In re­cent years, how­ev­er, it’s seen its rev­enue shrink as com­pe­ti­tion heats up and the pain­less cure ef­fec­tive­ly down­sized the mar­ket.

Mar­tin has pre­vi­ous­ly an­nounced his de­par­ture as board chair­man, amid an ex­ec­u­tive ex­o­dus that al­so claimed R&D head Nor­bert Bischoberg­er, CMO An­drew Cheng and com­mer­cial chief James Mey­ers (who is re­tir­ing).

Be­fore O’Day as­sumes his role on March 1, 2019, Gregg Al­ton — a 20-year vet­er­an of the com­pa­ny who’s served as gen­er­al coun­sel and, most re­cent­ly, chief pa­tient of­fi­cer — will man the fort as in­ter­im CEO.

In­vestors wel­comed the news, send­ing Gilead shares $GILD up 2.5%.

O’Day, who Jef­feries’ Michael Yee de­scribes as “pret­ty straight down the road” in terms of risk tak­ing with­out a his­to­ry of big M&A deal­ing, grad­u­ates from Roche as a 30-year vet­er­an of the Swiss phar­ma gi­ant, hav­ing start­ed with com­mer­cial and sales roles in 1987. Since tak­ing con­trol of the phar­ma unit in 2012, he’s over­seen the launch of sev­er­al po­ten­tial block­buster drugs in­clud­ing Hem­li­bra and Tecen­triq.

Baird’s Bri­an Sko­r­ney, mean­while, of­fers a de­cid­ed­ly glow­ing re­view of the new CEO:

(I)n his role at Roche, we think he has done a phe­nom­e­nal job at nav­i­gat­ing the com­pa­ny in­to a next gen­er­a­tion of prod­ucts (Ocre­vus, Hem­li­bra, po­latuzum­ab are just a cou­ple of prod­ucts we see as new, im­pact­ful block­buster drugs). Most im­por­tant­ly, we be­lieve the long his­to­ry at Roche makes him a choice that isn’t like­ly to break an al­ready good com­pa­ny. While we ex­pect that re­plac­ing the head of one of the strongest man­age­ment teams ever seen in biotech to be a chal­leng­ing role, we think that O’Day is high­ly qual­i­fied and should ease in­vestor con­cerns lead­ing in­to Mil­li­gan’s re­tire­ment.

While in­vestors keen­ly await a strate­gic plan and vi­sion from O’Day, an­a­lysts at Jef­feries laid out a pos­si­ble sce­nario:

We be­lieve O’Day will look to de­vel­op a strat­e­gy over the course of 2019 and it will in­clude a view on de­ploy­ing GILD’s cur­rent cash of ~$32B to­wards more on­col­o­gy as­sets and oth­er key ar­eas, such as in­flam­ma­tion and liv­er dis­eases. Note’s GILD’s cur­rent debt-to-EBIT­DA ra­tio stands at rough­ly ~2.6x so the com­pa­ny could still lever up to do more deals. (…) we can as­sume his plan-of-ac­tion for 2019 is to en­sure that: (1) HCV sta­bi­lizes and be­comes more “pre­dictable”, (2) HIV grows as Bik­tarvy con­tin­ues to reach record rev­enues, and (3) Yescar­ta grows each quar­ter as the com­pa­ny con­tin­ues to ex­pand its pres­ence in hema­tol­ogy (e.g. al­lo­gene­ic CAR-T) and sol­id tu­mors (neo-anti­gens).

Faced with a wan­ing hep C fran­chise, Gilead has swal­lowed Kite Phar­ma in a bid to be­come a leader in CAR-T, snap­ping up new tech­nolo­gies along the way. It is now up to O’Day to gal­va­nize the sales of Kite’s CAR-T ther­a­py Yescar­ta, which de­spite im­pres­sive sur­vival rates gen­er­at­ed a pal­try $183 mil­lion for the first nine months of 2018.

Mean­while in Basel, Genen­tech CEO Bill An­der­son will fill O’Day’s shoes.


Im­age: Daniel O’Day. ROCHE

Secretary of health and human services Alex Azar speaking in the Rose Garden at the White House (Photo: AFP)

Trump’s HHS claims ab­solute au­thor­i­ty over the FDA, clear­ing path to a vac­cine EUA

The top career staff at the FDA have vowed not to let politics get in the way of science when looking at vaccine data this fall. But Alex Azar, who happens to be their boss’s boss, apparently won’t even give them a chance to stand in the way.

In a new memorandum issued Tuesday last week, the HHS chief stripped health agencies under his purview — including the FDA — of their rulemaking ability, asserting all such power “is reserved to the Secretary.” Sheila Kaplan of the New York Times first obtained and reported the details of the September 15 bulletin.

Dan Skovronsky, Eli Lilly CSO

UP­DAT­ED: An­a­lysts are quick to pan Eli Lil­ly's puz­zling first cut of pos­i­tive clin­i­cal da­ta for its Covid-19 an­ti­body

Eli Lilly spotlighted a success for one of 3 doses of their closely-watched Covid-19 antibody drug Wednesday morning. But analysts quickly highlighted some obvious anomalies that could come back to haunt the pharma giant as it looks for an emergency use authorization to launch marketing efforts.

The pharma giant reported that LY-CoV555, developed in collaboration with AbCellera, significantly reduced the rate of hospitalization among patients who were treated with the antibody. The drug arm of the study had a 1.7% hospitalization rate, compared to 6% in the control group, marking a 72% drop in risk.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Eli Lilly CSO Dan Skovronsky (file photo)

#ES­MO20: Eli Lil­ly shows off the da­ta for its Verzenio suc­cess. Was it worth $18 bil­lion?

The press release alone, devoid of any number except for the size of the trial, added nearly $20 billion to Eli Lilly’s market cap back in June. Now investors and oncologists will get to see if the data live up to the hype.

On Sunday at ESMO, Eli Lilly announced the full results for its Phase III MonarchE trial of Verzenio, showing that across over 5,000 women who had had HR+, HER2- breast cancer, the drug reduced the odds of recurrence by 25%. That meant 7.8% of the patients on the drug arm saw their cancers return within 2 years, compared with 11.3% on the placebo arm.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Greg Friberg (File photo)

#ES­MO20: Am­gen team nails down sol­id ear­ly ev­i­dence of AMG 510’s po­ten­tial for NSCLC, un­lock­ing the door to a wave of KRAS pro­grams

The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at ASCO a little more than a year ago, there was high excitement about the first glimpse of efficacy from their Phase I study, with 5 of 10 evaluable non-small cell lung cancer patients demonstrating a response to the drug.

After decades of failure targeting KRAS, sotorasib offered the first positive look at a new approach that promised to open a door to a whole new approach by targeting a particular mutation to a big target that had remained “undruggable” for decades.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

#ES­MO20: Out to beat Tagris­so, J&J touts 100% ORR for EGFR bis­pe­cif­ic/TKI com­bo — fu­el­ing a quick leap to PhI­II

J&J’s one-two punch on EGFR-mutant non-small cell lung cancer has turned up some promising — although decidedly early — results, fueling the idea that there’s yet room to one up on third-generation tyrosine kinase inhibitors.

Twenty out of 20 advanced NSCLC patients had a response after taking a combination of an in-house TKI dubbed lazertinib and amivantamab, a bispecific antibody targeting both EGFR and cMET engineered on partner Genmab’s platform, J&J reported at ESMO. All were treatment-naïve, and none has seen their cancer progress at a median follow-up of seven months.

#ES­MO20: As­traZeneca aims to spur PRO­found shift in prostate can­cer treat­ment with Lyn­parza OS da­ta

AstraZeneca has unveiled the final, mature overall survival data that cemented Lynparza’s first approval in prostate cancer approval — touting its lead against rivals with the only PARP inhibitor to have demonstrated such benefit.

But getting the Merck-partnered drug to the right patients remains a challenge, something the companies are hoping to change with the new data cut.

The OS numbers on the subgroup with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer are similar to the first look on offer when the FDA expanded the label in May: Lynparza reduced the risk of death by 31% versus Xtandi and Zytiga. Patients on Lynparza lived a median of 19.1 months, compared to 14.7 months for the anti-androgen therapies (p = 0.0175).

Exelixis CEO Michael Morrissey (file photo)

#ES­MO20: Look out Mer­ck. Bris­tol My­ers and Ex­elix­is stake out their com­bo’s claim to best-in-class sta­tus for front­line kid­ney can­cer

Now that the PD-(L)1 checkpoints are deeply entrenched in the oncology market, it’s time to welcome a wave of combination therapies — beyond chemo — looking to extend their benefit to larger numbers of patients. Bristol Myers Squibb ($BMY} and Exelixis {EXEL} are close to the front of that line.

Today at ESMO the collaborators pulled the curtain back on some stellar data for their combination of Opdivo (the PD-1) and Cabometyx (the TKI), marking a significant advance for the blockbuster Bristol Myers franchise while offering a big leg up for the team at Exelixis.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.

Donald Trump and White House chief of staff Mark Meadows, before boarding Marine One (Getty Images)

Pric­ing deal col­laps­es over Big Phar­ma's re­fusal to is­sue $100 'cash card­s' be­fore the elec­tion — re­port

Late in August, as negotiations on a pricing deal with President Trump reached a boiling point, PhRMA president Stephen Ubl sent an email update to the 34 biopharma chiefs that sit on his board. He wrote that if the industry did not agree to pay for a $100 “cash card” sent to seniors before November, White House chief of staff Mark Meadows was going to tell the news media Big Pharma was refusing to “share the savings” with the elderly — and that all of the blame for failed drug pricing negotiations would lie squarely on the industry.

#ES­MO20: It’s not just Keytru­da any­more — Mer­ck spot­lights 3 top ear­ly-stage can­cer drugs

Any $12 billion megablockbuster in the portfolio tends to overshadow everything else in the pipeline. Which is something Merck can tell you a little bit about.

Keytruda not only dominates the PD-(L)1 field, it looms over everything Merck does, to the point some analysts wonder if Merck is a one-trick pony.

There’s no shortage of Keytruda data on display at ESMO this weekend, but now the focus is shifting to the future role of new drugs and combos in maintaining that lead position for years to come. And the pharma giant has a special focus for 3 early-stage efforts where Roger Perlmutter’s oncology team is placing some big bets.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 90,300+ biopharma pros reading Endpoints daily — and it's free.